Carmot Therapeutics Highlights Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at ObesityWeek®

DALLAS, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people with metabolic disease

Website link :https://adquash.com/news_q.php?str=Carmot_Therapeutics_Highlights_Clinical_Data_from_its_Pipeline_of_Treatments_for_Obesity_and_Diabetes_at_ObesityWeek®_384

Glofitamab by F. Hoffmann-La Roche for Non-Hodgkin Lymphoma: Likelihood of Approval

Glofitamab is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for Non-Hodgkin Lymphoma have a 74% phase tra

Website link :https://adquash.com/news_q.php?str=Glofitamab_by_F._Hoffmann-La_Roche_for_Non-Hodgkin_Lymphoma:_Likelihood_of_Approval_1181

Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval

Tezepelumab is under clinical development by Amgen and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary

Website link :https://adquash.com/news_q.php?str=Tezepelumab_by_Amgen_for_Chronic_Obstructive_Pulmonary_Disease_(COPD):_Likelihood_of_Approval_1184

Disitamab vedotin by Seagen for Urethral Cancer: Likelihood of Approval

Disitamab vedotin is under clinical development by and currently in Phase II for Urethral Cancer. According to GlobalData, Phase II drugs for Urethral Cancer does not have sufficient historical data t

Website link :https://adquash.com/news_q.php?str=Disitamab_vedotin_by_Seagen_for_Urethral_Cancer:_Likelihood_of_Approval_694

Tiragolumab by Genentech USA for Gastric Cancer: Likelihood of Approval

Tiragolumab is under clinical development by and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) in

Website link :https://adquash.com/news_q.php?str=Tiragolumab_by_Genentech_USA_for_Gastric_Cancer:_Likelihood_of_Approval_692

Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Cevostamab?

Cevostamab is a monoclonal antibody commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Relapsed Multiple Myeloma;Refractory Multiple Myeloma. According to Globaldata, it is inv

Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_F._Hoffmann-La_Roche’s_Cevostamab_108

Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Balovaptan?

Balovaptan is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Post-Traumatic Stress Disorder (PTSD). According to Globaldata, it is involved in 17 clinical

Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_F._Hoffmann-La_Roche’s_Balovaptan_114

Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and Pancreatic Cancers

DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related

Website link :https://adquash.com/news_q.php?str=Gradalis-GRAD1405-bi-shRNAi-Candidate-First-to-Show-Positive-Impact-on-Three-Key-KRAS-Mutations-Identified-in-Drug-Resistant-Lung-Colon-and-Pancreatic-Cancers

Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s OpRegen?

OpRegen is a cell therapy commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Geographic Atrophy. According to Globaldata, it is involved in 2 clinical trials, which are ongoing

Website link :https://adquash.com/news_q.php?str=Risk_adjusted_net_present_value:_What_is_the_current_valuation_of_F._Hoffmann-La_Roche’s_OpRegen_115

MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval

MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase III drugs for Influenza A Virus, H3N2 Subty

Website link :https://adquash.com/news_q.php?str=MRNA-1083_by_Moderna_for_Influenza_A_Virus,_H3N2_Subtype_Infections:_Likelihood_of_Approval_1189

Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Epcoritamab is under clinical development by and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leu

Website link :https://adquash.com/news_q.php?str=Epcoritamab_by_Genmab_for_Refractory_Chronic_Lymphocytic_Leukemia_(CLL):_Likelihood_of_Approval_701

BNT-142 by BioNTech for Peritoneal Cancer: Likelihood of Approval

BNT-142 is under clinical development by and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR)

Website link :https://adquash.com/news_q.php?str=BNT-142_by_BioNTech_for_Peritoneal_Cancer:_Likelihood_of_Approval_712